Dermatophagoides microceras
Also known as: MPO-ANCA, PR3-ANCA
Use
For diagnosis and monitoring inflammatory activity in primary systemic small vessel vasculitides. The anti-PR3-ANCA Immunoassay is useful for confirming positive ANCA results by IFA, particularly with the cANCA pattern. Presence of anti-PR3 antibodies is highly specific for Wegener granulomatous (WG) disease, for which the sensitivity is reported to be 98%. Levels of anti-PR3 are elevated during active phases of disease and lower during remission. Monitoring anti-PR3 levels, therefore, can aid in disease management. The anti-MPO-ANCA Immunoassay is useful for confirming positive ANCA results by IFA, particularly with the P-ANCA pattern. Presence of anti-MPO antibodies is highly specific for idiopathic and vasculitis-associated crescentic glomerulonephritis, classic polyarteritis nodosa, Churg-Strauss syndrome, and polyangiitis overlap syndrome without renal involvement. Levels of anti-MPO are elevated during active phases of disease and lower during remission. Therefore, monitoring anti-MPO levels can aid in disease management.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
ANCA: indirect fluorescent antibody (IFA); MPO and PR3: Multiplex Flow Immunoassay
Biomarkers
LOINC Codes
- 14036-8 - D microceras IgE Qn
- 46266-3 - Myeloperoxidase Ab Ser IA-aCnc
- 46267-1 - Proteinase3 Ab Ser IA-aCnc
- 14277-8 - c-ANCA Titr Ser IF
- 14278-6 - p-ANCA Titr Ser IF
- 49503-6 - p-ANCA atypical Titr Ser IF
- 14036-8 - D microceras IgE Qn
Result Turnaround Time
4-7 days
Related Documents
For more information, please review the documents below
Specimen
Unknown
Volume
Not provided
Minimum Volume
Not provided
Causes for Rejection
Hemolysis; lipemia; gross bacterial contamination
Other tests from different labs that may be relevant
